UroGen Pharma (NASDAQ:URGN) Price Target Lowered to $16.00 at The Goldman Sachs Group

UroGen Pharma (NASDAQ:URGN) had its target price reduced by The Goldman Sachs Group from $22.00 to $16.00 in a report released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Several other analysts have also commented on the stock. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. HC Wainwright reduced their target price on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Scotiabank initiated coverage on UroGen Pharma in a report on Wednesday. They set a “sector outperform” rating and a $23.00 price target for the company. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $32.86.

UroGen Pharma Stock Down 6.9 %

Shares of NASDAQ:URGN opened at $9.67 on Thursday. UroGen Pharma has a 52-week low of $8.94 and a 52-week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a fifty day moving average of $10.50 and a two-hundred day moving average of $11.21. The stock has a market cap of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. On average, research analysts expect that UroGen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On UroGen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC raised its stake in shares of UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company’s stock valued at $293,000 after acquiring an additional 19,670 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after purchasing an additional 5,890 shares during the period. State Street Corp raised its position in UroGen Pharma by 5.9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock valued at $9,774,000 after purchasing an additional 42,907 shares in the last quarter. Barclays PLC boosted its stake in shares of UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after buying an additional 48,040 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after buying an additional 34,248 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.